Orapred Tablet, Orally Disintegrating
FDA Label NDC 59212-701

48 label sections · Submitted to the FDA by Advanz Pharma (us) Corp. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Advanz Pharma (us) Corp. for the product Orapred (NDC 59212-701). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 1.1 allergic conditions, 1.2 dermatologic diseases, 1.3 endocrine conditions, 1.4 gastrointestinal diseases, 1.5 hematologic diseases, 1.6 neoplastic conditions, 1.7 nervous system conditions, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

8.2 Lactation

Risk Summary
Prednisolone is present in human milk. Published reports suggest infant daily doses are estimated to be less than 1%  of the maternal daily dose. No adverse effects in the breastfed infant have been reported following maternal administration of prednisolone during breastfeeding. There are no available data on the effects of prednisolone on milk  production. High doses of corticosteroids administered to lactating women for long periods could potentially produce problems in the breastfed infant including growth and development and interfere with endogenous corticosteroid production (see Clinical Considerations) [see Use in Specific Populations ( 8.4 )].The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Orapred and any potential adverse  effects on the breastfed child from Orapred or from the mother's underlying condition.

Clinical Considerations
In order to minimize exposure, the lowest dose should be prescribed to a lactating women to achieve the desired clinical effect.

* Please review the disclaimer below.